knowledge -WSS

knowledge

author：focus 2025-10-01 02:12:34 - browse：65457

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Biohaven protein

focus

Wikipedia

WSS

Readout LOUD podcast: How biotech is using artificial intelligence

Health insurers say they are turning to AI to cut costs, improve care

Doctors' information doesn't help them choose wisely when sick

Lab trade group sues FDA to halt regulation of lab

Robert F. Kennedy is pitching centrism on health, even on abortion

Scientists successfully use ultrasound imaging to map brain activity

focus

knowledge

Wikipedia

Malaria cases in Florida and Texas: Here’s what you need to know

KalVista pill reduced swelling 'attacks' caused by genetic disease

Novavax promises a turnaround & Lilly roils the obesity market

What should King Charles tell the public about his cancer?

Malaria cases in Florida and Texas: Here’s what you need to know

Biogen Alzheimer’s drug launch off to slow start

Virginia high school admissions case could be legal follow

Akili, maker of video game for ADHD, to be acquired for 34 million

Medical leaders decry Supreme Court decision on affirmative action

Why did Pfizer dish out millions for a Super Bowl ad?

focus

Scientists successfully use ultrasound imaging to map brain activity

Biohaven protein

Medicare threatens to cut off funding for HCA's Mission hospital

Adam's Biotech Scorecard: Do Sarepta's exon

Addiction doctors spar with methadone clinics over legislation

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

focus

focus

Wikipedia

leisure time